Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes - Summary - MDSpire

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes

  • By

  • Abiola Bolarinwa

  • Madhu Nagaraj

  • Saurabh Zanwar

  • Nadine Abdallah

  • P. Leif Bergsagel

  • Moritz Binder

  • Francis Buadi

  • Saurabh Chhabra

  • Joselle Cook

  • David Dingli

  • Angela Dispenzieri

  • Morie A. Gertz

  • Wilson Gonsalves

  • Suzanne Hayman

  • Prashant Kapoor

  • Taxiarchis Kourelis

  • Nelson Leung

  • Yi Lin

  • Eli Muchtar

  • Ricardo Parrondo

  • Vivek Roy

  • Taimur Sher

  • Mustaqeem Siddiqui

  • Rahma Warsame

  • Amie Fonder

  • Miriam Hobbs

  • Yi Lisa Hwa

  • Michelle Rogers

  • Udit Yadav

  • J. Erin Wiedmeier-Nutor

  • Linda B. Baughn

  • S. Vincent Rajkumar

  • Rafael Fonseca

  • Sikander Ailawadhi

  • Shaji Kumar

  • April 4, 2025

  • 0 min

Share

Objective:

To evaluate the efficacy and outcomes of venetoclax-based combination therapies in relapsed/refractory multiple myeloma (RRMM), particularly considering the impact of specific secondary cytogenetic abnormalities.

Key Findings:
  • Response rates for venetoclax-based combinations were high, with 80% in a phase 2 study and ≥96% VGPR in other studies, but concerns about overall survival (OS) due to higher infection rates in venetoclax arms were noted.
  • Median progression-free survival (PFS) was 24.8 months for t(11;14) subgroup and 22.8 months for non-t(11;14) subgroup.
Interpretation:

While venetoclax-based combinations show promising efficacy in RRMM, particularly in t(11;14) patients, further research is needed to clarify the impact of secondary cytogenetic abnormalities on treatment outcomes.

Limitations:
  • Lack of data on the impact of secondary cytogenetic abnormalities on venetoclax efficacy limits the conclusions that can be drawn.
  • Studies primarily involved less heavily pretreated cohorts, which may not reflect broader patient populations.
Conclusion:

Venetoclax-based therapies demonstrate significant potential in treating RRMM, especially in patients with t(11;14), but further research is needed to understand the role of secondary cytogenetic abnormalities.

Original Source(s)

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes

  • by Abiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, Nadine Abdallah, P. Leif Bergsagel, Moritz Binder, Francis Buadi, Saurabh Chhabra, Joselle Cook, David Dingli, Angela Dispenzieri, Morie A. Gertz, Wilson Gonsalves, Suzanne Hayman, Prashant Kapoor, Taxiarchis Kourelis, Nelson Leung, Yi Lin, Eli Muchtar, Ricardo Parrondo, Vivek Roy, Taimur Sher, Mustaqeem Siddiqui, Rahma Warsame, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Michelle Rogers, Udit Yadav, J. Erin Wiedmeier-Nutor, Linda B. Baughn, S. Vincent Rajkumar, Rafael Fonseca, Sikander Ailawadhi, Shaji Kumar

  • April 4, 2025

Related Content

Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence

Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines

Case Report: Cytoreductive surgery as a therapeutic attempt in the treatment of extramedullary plasmacytoma